Skip to main content
Terug
ESPR logo

Esperion Therapeutics, Inc.

Datakwaliteit: 100%
ESPR
NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
€ 2,76
▲ € 0,14 (5,34%)
Marktkapitalisatie: 573,83M
Dagbereik
€ 2,66 € 2,86
52-Weeksbereik
€ 0,69 € 4,18
Volume
4.553.922
50D / 200D Gem.
€ 3,18 / € 2,62
Vorige Slotkoers
€ 2,62

Quick Summary

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (631 peers)

Metriek Aandeel Sector Mediaan
P/E -25,3 0,2
P/B — 3,0
ROE % — 3,5
Net Margin % -5,6 3,8
Rev Growth 5Y % 50,6 9,7
D/E — 0,2

Koersdoel Analisten

Hold
€ 9,00 +226.1%
Forward K/W
37,40
Forward WPA
€ 0,07
WPA Groei (sch.)
+0,0%
Omzet Sch.
408,73M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 1,67
€ 1,27 – € 2,07
 1,12B 1
FY2029 € 1,17
€ 0,89 – € 1,45
 884,55M 1
FY2028 € 0,34
-€ 0,63 – € 1,17
 553,23M 3

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-03-10 € 0,24 € 0,22 -9,6%
2025-11-06 -€ 0,09 -€ 0,16 -77,8%
2025-08-05 -€ 0,17 -€ 0,02 +88,2%
2025-05-06 -€ 0,18 -€ 0,21 -16,7%
2025-03-04 -€ 0,14 -€ 0,10 +28,6%
2024-11-07 -€ 0,14 -€ 0,15 -7,1%
2024-08-12 -€ 0,15 -€ 0,05 +66,7%
2024-05-07 € 0,05 € 0,34 +580,0%

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Belangrijkste Punten

Revenue grew 50,56% annually over 5 years — strong growth
Negative free cash flow of -12,90M
PEG of 0,56 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 29,25%
Capital efficient — spends only 0,05% of revenue on capex
ROIC of 18,37% — excellent capital efficiency

Groei

Revenue Growth (5Y)
50,56%
Revenue (1Y)21,31%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROIC18,37%
Net Margin-5,63%
Op. Margin14,95%

Veiligheid

Debt / Equity
N/A
Current Ratio0,56
Interest Coverage0,71

Waardering

P/E Ratio
-25,30
Forward P/E37,40
P/B RatioN/A
EV/EBITDA15,83
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 21,31% Revenue Growth (3Y) 86,15%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 50,56% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 403,14M Net Income (TTM) -22,68M
ROE N/A ROA -4,87%
Gross Margin 67,95% Operating Margin 14,95%
Net Margin -5,63% Free Cash Flow (TTM) -12,90M
ROIC 18,37% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,56
Interest Coverage 0,71
Dividends
Dividend Yield 0,00% Payout Ratio 0,00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -25,30 Forward P/E 37,40
P/B Ratio N/A P/S Ratio 1,42
PEG Ratio 0,56 Forward PEG N/A
EV/EBITDA 15,83 Fwd EV/EBITDA N/A
Forward P/S 1,40 Fwd Earnings Yield 2,67%
FCF Yield -2,25%
Market Cap 573,83M Enterprise Value 953,98M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 403,14M 332,31M 116,33M 75,48M 78,45M
Net Income -22,68M -51,75M -209,25M -233,66M -269,11M
EPS (Diluted) -0,11 -0,28 -2,03 -4,33 -11,03
Gross Profit 273,91M 263,71M 73,07M 48,51M 64,23M
Operating Income 60,27M 54,40M -155,56M -179,50M -226,73M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 465,89M 343,82M 205,80M 247,94M 381,59M
Total Liabilities 767,85M 732,54M 660,79M 571,72M 578,53M
Shareholders' Equity -301,97M -388,72M -454,99M -323,78M -196,94M
Total Debt 548,00M 591,21M 540,95M 260,95M 260,20M
Cash & Equivalents 167,85M 144,76M 82,25M 124,78M 208,89M
Current Assets 167,85M 338,00M 201,07M 246,68M 328,97M
Current Liabilities 300,81M 246,23M 156,22M 92,31M 73,35M